

Amendments To The Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

In the Claims:

What is claimed is:

Claims 1-7 (Cancelled)

8. (Currently Amended) ~~The compound of claim 4~~ A compound of Formula (I)



or a salt or solvate thereof, wherein

R¹ is cyano, nitro, halogen, haloalkyl, heterocyclyl, hydroxy, alkoxy, haloalkoxy, -OC(O)R⁶, -CO₂R⁶, -CONHR⁶, -C(O)R⁶, -S(O)_nR⁶, -SO₂N(R⁶)₂, -NHC(O)R⁶, or -NHSO₂R⁶;

R² is H, cyano, nitro, halogen, haloalkyl, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, haloalkoxy, -OC(O)R⁶, or aryl;

R³ and R⁴ each are independently -(CH₂)_x-R⁵,

where x is 0 to 6, and

R⁵ is selected from H, alkyl, hydroxy, haloalkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, -C(O)OR⁷, or -N(R⁸)₂;

each R⁶ independently is H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, aralkyl, heteroaryl, or heteroaralkyl;

each R⁷ independently is H, alkyl, cycloalkyl, aryl;

each R⁸ independently is H or alkyl; and R⁹ is H, cyano, nitro, halogen, haloalkyl, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, haloalkoxy, -OC(O)R⁸, or aryl;
and the compound is selected from:

N-(cyclopropylmethyl)-*N*-(4-nitro-1-naphthyl)-*N*-propylamine;

N-cyclohexyl-*N*-methyl-4-nitro-1-naphthalenamine;

N-(4-nitro-1-naphthyl)-*N,N*-dipropylamine;
N-butyl-*N*-methyl-*N*-(4-nitro-1-naphthyl)amine;
4-[ethyl(2-methyl-2-propenyl)amino]-1-naphthonitrile;
N-butyl-*N*-ethyl-4-nitro-1-naphthalenamine;
4-[butyl(methyl)amino]-1-naphthonitrile;
4-[(cyclopropylmethyl)(propyl)amino]-1-naphthonitrile;
*N*¹-ethyl-*N*²,*N*²-dimethyl-*N*¹-(4-nitro-1-naphthyl)-1,2-ethanediamine;
4-(propylamino)-1-naphthonitrile;
4-[(3-hydroxypropyl)amino]-1-naphthonitrile;
3-[(4-nitro-1-naphthyl)amino]propan-1-ol;
4-[(cyclopropylmethyl)amino]-1-naphthalenecarbonitrile;
4-[(cyclopropylmethyl)[3-(1-piperidinyl)propyl]amino]-1-naphthalene
carbonitrile trifluoroacetate;
4-[(cyclopropylmethyl)(3-hydroxypropyl)amino]-1-
naphthalenecarbonitrile;
4-nitro-*N*-(2,2,2-trifluoroethyl)-1-naphthalenamine;
4-bromo-*N*-(2,2,2-trifluoroethyl)-1-naphthalenamine;
4-bromo-*N,N*-bis(2,2,2-trifluoroethyl)-1-naphthalenamine;
4-[(2,2,2-trifluoroethyl)amino]-1-naphthalenecarbonitrile;
4-[bis(2,2,2-trifluoroethyl)amino]-1-naphthalenecarbonitrile;
4-[propyl(2,2,2-trifluoroethyl)amino]-1-naphthalenecarbonitrile;
4-[2-propen-1-yl(2,2,2-trifluoroethyl)amino]-1-naphthalenecarbonitrile;
and
4-[(2-hydroxyethyl)(2,2,2-trifluoroethyl)amino]-1-naphthalenecarbonitrile.

9. (Cancelled)

10. (Currently Amended) A pharmaceutical composition comprising a compound according to claim[[s 1-]]8, and a pharmaceutically acceptable carrier.

Claims 11-15 (Cancelled)

16. (Currently Amended) A method for the treatment or prophylaxis of conditions or disorders that respond to selective androgen receptor modulation comprising the administration of a compound according to ~~any one of~~ claim[[s 1-]]8.

17. (Currently Amended) A method for the treatment or prophylaxis of osteoporosis, muscle wasting, frailty, cardiovascular disease, breast cancer, uterine cancer, prostatic hyperplasia, prostate cancer, dyslipidemia, menopausal vasomotor conditions, urinary incontinence, arteriosclerosis, libido enhancement, depression, uterine fibroid disease, aortic smooth muscle cell proliferation, endometriosis, or ADAM comprising the administration of a compound according to ~~any one of claim~~[[s 1-]]8.